Featured Research

from universities, journals, and other organizations

Aspirin may reduce the risks of reoccurring blood clots

Date:
August 25, 2014
Source:
American Heart Association
Summary:
Aspirin may be a promising alternative for those who can’t take long-term anticoagulant drugs that prevent clots from reoccurring in the veins, according to new research. According to researchers, without treatment, people who have blood clots in their veins with no obvious cause have on average a 10 percent risk of another clot within the first year and a 5 percent risk per year thereafter.

Aspirin may be a promising alternative for those who can’t take long-term anticoagulant drugs that prevent clots from reoccurring in the veins, according to new research in the American Heart Association journal Circulation.

In a combined analysis of two similar independent studies, 1,224 patients who received 100 mg of aspirin a day to treat blood clots were monitored for at least two years. In the International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism or INSPIRE analysis, researchers found that aspirin reduced the risk of recurring blood clots by up to 42 percent.

Venous thromboembolism (VTE) are blood clots in veins. The blood clot can occur in the deep veins of the legs (deep vein thrombosis) and can break apart and travel to the lungs, where they block off arteries in the lungs (pulmonary embolism).

According to researchers, without treatment, people who have blood clots in their veins with no obvious cause have on average a 10 percent risk of another clot within the first year and a 5 percent risk per year thereafter.

“The treatment is warfarin or a newer anticoagulant usually given for at least six to 12 months to prevent a further blood clot,” said John Simes, M.D., lead author of study and director of the National Health and Medical Research Council Trials Centre and professor at the University of Sydney in Australia. “However, these people continue to be at risk.”

Co-author Cecilia Becattini, M.D., added, “Aspirin does not require laboratory monitoring, and is associated with about a 10-fold lower incidence of bleeding compared with oral anticoagulants. We are convinced that it will be an alternative for extended prevention of venous thromboembolism after 6–12 months of anticoagulant treatment.”

Although the study yielded clear results, researchers advise patients to talk to their doctor about taking aspirin after stopping treatment with anticoagulants.

“It is not recommended that aspirin be given instead of anticoagulant therapy, but rather be given to patients who are stopping anticoagulant therapy or for whom such treatments are considered unsuitable,” Simes said.

“Although less effective, aspirin is inexpensive, easily obtainable, safe and familiar to patients and clinicians worldwide. If cost is the main consideration, aspirin is a particularly useful therapy. The costs of treating future thromboembolic events is greater than the cost of the preventive treatment.”


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Simes, C. Becattini, G. Agnelli, J. W. Eikelboom, A. C. Kirby, R. Mister, P. Prandoni, T. A. Brighton. Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration. Circulation, 2014; DOI: 10.1161/CIRCULATIONAHA.114.008828

Cite This Page:

American Heart Association. "Aspirin may reduce the risks of reoccurring blood clots." ScienceDaily. ScienceDaily, 25 August 2014. <www.sciencedaily.com/releases/2014/08/140825185553.htm>.
American Heart Association. (2014, August 25). Aspirin may reduce the risks of reoccurring blood clots. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2014/08/140825185553.htm
American Heart Association. "Aspirin may reduce the risks of reoccurring blood clots." ScienceDaily. www.sciencedaily.com/releases/2014/08/140825185553.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins